Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An Italian cost-minimization analysis

Neurological Sciences

Volumn 35, Issue 7, 2014, Pages 1023-1034

  Lazzaro, Carlo ^a   Lopiano, Leonardo ^b   Cocito, Dario ^b  

^a Studio di Economia Sanitaria   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; CIDP; Cost minimization analysis; Immunoglobulin; IVIG; SCIG

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COST MINIMIZATION ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; LEISURE; PREMEDICATION; AGE; CAREGIVER; COST; ECONOMICS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; ITALY; LONGITUDINAL STUDY; MALE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PROCEDURES; PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; AGE FACTORS; CAREGIVERS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INFUSIONS, SUBCUTANEOUS; ITALY; LONGITUDINAL STUDIES; MALE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SENSITIVITY AND SPECIFICITY;

EID: 84903382264     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1632-9     Document Type: Article

References (37)

1. Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride J-E, O'Reilly D, Chalk C, Levine M, Goeree R (2010) Costutility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 8:14. http://www.resource-allocation.com/content/8/1/14. Accessed 1 June 2013
2. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M (2005) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. doi:10.1002/14651858.CD004429.pub2
3. Lewis RA (2007) Chronic inflammatory demyelinating polyneuropathy. Neurol Clin 25:71-87
4. Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK (1999) Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in South-East England. J Neurol Neurosurg Psychiatry 66:677-680 (Pubitemid 29186982)
5. McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V (1999) Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 46:910-913
6. Mygland A, Monstad P (2001) Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 8:157-165 (Pubitemid 32269635)
7. Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, Mutani R, Calvo A (2007) Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 78:1349-1353
8. Cocito D (2011) The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 16:150-152
9. Cocito D, Serra G, Paolasso I, Barilà DA, Lopiano L, Cattel L (2012) Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies. J Peripher Nerv Syst 17:426-428
10. Drummond MF, Schulper MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford
11. Gold MR, Siegel JE, Russel LB, Weinstein MC (eds) (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
12. De Pietro C (2005) Gestire il personale nelle aziende sanitarie italiane. McGraw-Hill, Milan
13. Lazzaro C, Bianchi C, Peracino L, Zacchetti P, Uccelli A (2009) Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon b-1b. Neurol Sci 30:21-31
14. Automobile Club d'Italia. Costi chilometrici 2013. http://www.aci.it/ servizionline/costichilometrici. Accessed 1 June 2013
15. Torrino Management. Prontuario Farmaceutico 2012 (Last update 05/06/2013). Rome: Torrino Management, 2013. http://www.torrinomedica.it/ farmaci/prontuario/indice-prontuario.asp. Accessed 7 June 2013
16. Ministero della Salute. Decreto 18 ottobre 2012. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. (13A00528) Supplemento Straordinario n. 2 alla Gazzetta Ufficiale n. 23 del 28 Gennaio 2013, Serie generale
17. Brouwer W, Rutten F, Koopmanschap MA (2001) Costing in economic evaluations. In: Drummond M, McGuire A (eds) Economic evaluation in health care: merging theory with practice. Oxford University Press, Oxford, pp 68-93
18. Sistema Statistico Nazionale - Istituto Nazionale di Statistica. Popolazione Residente per età, sesso e stato civile al 18 gennaio 2012. http://demo.istat.it/pop2012/index.html. Accessed 21 May 2013
19. Ministero della Sanità. Decreto 18 maggio 2001, n. 279. Regolamento di istituzione della rete nazionale delle malattie rare e di esenzione dalla partecipazione al costo delle relative prestazioni sanitarie, ai sensi dell'articolo 5, comma 1, lettera b), del decreto legislativo 29 aprile 1998, n. 124. Supplemento Ordinario alla Gazzetta Ufficiale n. 160 del 12 Luglio 2001, Serie generale: 11
20. Hodgson TA, Meiners MR (1982) Cost-of illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 6:429-462
21. Posnet J, Ian S (1996) Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 5:13-23
22. Federproprietà, Uppi, Confappi, Fesica Confsal, Confsal Fisals. Contratto collettivo nazionale di lavoro colf e badanti. Rome: 12 June 2008
23. Ente Bilaterale Colf e Badanti. Contratto collettivo nazionale di lavoro colf e badanti 2012. http://www.ebilcoba.it. Accessed 5 May 2013
24. Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB (2008) An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics 26:269-280 (Pubitemid 351790246)
25. Banca d'Italia. I bilanci delle famiglie italiane nell'anno 2010. Supplementi al Bollettino Statistico. Nuova serie. Anno XX - Numero 8. Rome: Banca d'Italia, 10 February 2012:63
26. Agenzia delle Entrate. Annuario del contribuente 2013. Rome: Agenzia delle Entrate, 28 March 2012:69
27. Istituto Nazionale per la Previdenza Sociale. Canale informazioni. Minimali giornalieri di retribuzione. http://www.inps.it/portale/default.aspx? sID=%3b0%3b5637%3b&lastMenu=5637&iMenu=1&p4=2&bi=22&link=I contributi da lavoro. Accessed 9 May 2013
28. Sistema Statistico Nazionale - Istituto Nazionale di Statistica. Prezzi al consumo. Aprile 2013. Rome: ISTAT, 14 May 2013. http://www.istat.it/it/ archivio/90023. Accessed 21 May 2013
29. Briggs AH, O'Brien BJ, Blackhouse G (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 23:377-401 (Pubitemid 34508080)
30. Briggs A, Schulper M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
31. Briggs AH (2001) Handling uncertainty in economic evaluation. In: Drummond M, McGuire A (eds) Economic evaluation in health care: merging theory with practice. Oxford University Press, Oxford, pp 172-214
32. Boriani G, Braunschweig F, Deharo JC, Leyva F, Lubinski A, Lazzaro C (2013) Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon. Europace. doi:10.1093/europace/eut133
33. Calizzani G, Lanzoni M, Candura F, et al. Analisi della domanda dei principali medicinali plasmaderivati in Italia. Anni 2007-2011. Rome: Istituto Superiore di Sanità, 2012:148. (Rapporti ISTISAN 12/53)
34. McCrone P, Chisholm D, Knapp M, Hughes R, Comi G, Dalakas MC, Illa I, Kilindireas C, Nobile-Orazio E, Swan A, Van den Bergh P, Willison HJ, INCAT Study Group (2003) Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 10:687-694 (Pubitemid 38030879)
35. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217-227 (Pubitemid 27296586)
36. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) ISPOR Task Force on Good Research Practices-Modeling Studies Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 6:9-17 (Pubitemid 36228345)
37. Associazione Italiana Neuropatie Periferiche. Centri di Riferimento. http://www.neuropatia.it/. Accessed 1 June 2013